Details

Autor(en) / Beteiligte

• Knight, K.
• Choong, J.X.
• McKee, R.F.
• Anderson, J.H.
• Horgan, P.G.
• McMillan, D.C.
• McDonald, A.
• Roxburgh, C.S.

Titel

The Influence of Systemic Inflammation on Treatment Response and Survival in Anal Squamous Cell Cancer

Ist Teil von

• Clinical oncology (Royal College of Radiologists (Great Britain)), 2021-01, Vol.33 (1), p.e22-e30

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The incidence of anal squamous cell cancer (SCCA) is rising. Although chemoradiotherapy (CRT) provides a chance of cure, a proportion of patients have an incomplete response or develop recurrence. This study assessed the value of inflammation-based prognostic indicators, including the modified Glasgow Prognostic Score (mGPS) and neutrophil:lymphocyte ratio (NLR), in patients with SCCA treated by CRT with curative intent. Patients with histologically confirmed SCCA were identified from pathology records. Medical records were retrospectively reviewed and clinical, pathological and treatment characteristics were abstracted. The mGPS (0 = normal C-reactive protein [CRP] and albumin, 1 = CRP >10 mg/l and 2 = CRP >10 mg/l and albumin <35 mg/l) and NLR were calculated from routine blood tests obtained prior to CRT. In total, 118 patients underwent CRT for SCCA between December 2007 and February 2018. Of these, 99 patients had appropriate pretreatment blood results available. Systemic inflammation as indicated by NLR >3 and mGPS >0 was present in 41% and 39% of patients, respectively. Most patients had T2 or larger tumours (n = 85, 86%) without nodal involvement (n = 64, 65%). An elevated mGPS was associated with more advanced T-stage (56% versus 35%, P = 0.036). NLR >5 was associated with nodal positivity (56% versus 31%, P = 0.047). On multivariate analysis, more advanced T-stage (odds ratio 7.49, 95% confidence interval 1.51–37.20, P = 0.014) and a raised mGPS (odds ratio 5.13, 95% confidence interval 1.25–21.14, P = 0.024) were independently related to incomplete CRT response. An elevated mGPS was prognostic of inferior survival (hazard ratio 3.09, 95% confidence interval 1.47–6.50, P = 0.003) and cancer-specific survival (hazard ratio 4.32, 95% confidence interval 1.54–12.15, P = 0.006), independent of TNM stage. Systemic inflammation, as measured by the mGPS, is associated with an incomplete CRT response and is independently prognostic of inferior survival in patients with SCCA. The mGPS may offer a simple marker of inferior outcome that could be used to identify high-risk patients. •Systemic inflammation in patients with solid tumours carries a poor prognosis.•The mGPS and NLR measure systemic inflammation.•Patients with anal cancer and a raised mGPS had poorer survival.•Incomplete response to curative chemoradiotherapy was associated with a raised mGPS.